Ernexa Therapeutics Inc. (ERNA)
ERNA Stock Price Chart
Explore Ernexa Therapeutics Inc. interactive price chart. Choose custom timeframes to analyze ERNA price movements and trends.
ERNA Company Profile
Discover essential business fundamentals and corporate details for Ernexa Therapeutics Inc. (ERNA) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
29 Aug 1991
Employees
6.00
Website
https://www.ernexatx.comCEO
Sanjeev Luther
Description
Ernexa Therapeutics Inc. is a biotechnology firm currently in its preclinical development phase, specializing in the creation of therapeutic interventions using induced mesenchymal stem cells (iMSCs). The company's primary focus lies in addressing solid tumor cancers and a range of autoimmune diseases. Its flagship candidate, ERNA-101, is an allogeneic iMSC designed to release pro-inflammatory cytokines, namely IL-7 and IL-15, intended for the treatment of ovarian cancer. Additionally, Ernexa is developing ERNA-102, an iMSC product engineered to secrete the anti-inflammatory cytokine IL-10, aimed at managing rheumatoid arthritis. The company has a licensing arrangement in place with Factor Bioscience Limited. Established in 2018, this Cambridge, Massachusetts-based entity operated as Eterna Therapeutics Inc. until its rebranding to Ernexa Therapeutics in March 2025.
ERNA Financial Timeline
Browse a chronological timeline of Ernexa Therapeutics Inc. corporate events including earnings releases, dividend announcements, and stock splits.
ERNA Stock Performance
Access detailed ERNA performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
